Intensity Therapeutics INTS
NASDAQ INTS
$4.86 -0.02 (-0.41%)
At close: Aug 21, 2026 · 4:00 PM EDT

Intensity Therapeutics (INTS) Cash from Investing Activities (2023 - 2024)

Intensity Therapeutics' (INTS) quarterly Cash from Investing Activities came in at $3.1 million in Q3 2024, up 135.05% YoY from $1.3 million in Q4 2023, and up 51766.67% on a QoQ basis from -$6000.0 in Q2 2024.

Intensity Therapeutics (INTS) Cash from Investing Activities (2023 - 2024) Analysis & Trends

Intensity Therapeutics (INTS) has 2 years of Cash from Investing Activities data on file, last reported at $3.1 million in Q3 2024.

  • Quarterly Cash from Investing Activities rose 135.05% year-over-year to $3.1 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $3.1 million (up 211.95% YoY) and the FY2024 annual result came in at $6.4 million, up 205.5% from the prior year.
  • Cash from Investing Activities climbed to $3.1 million in Q3 2024, from -$6000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $3.3 million in Q1 2024 to a low of -$8.8 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 329.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -49.35 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -363.46 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -3.17 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 24.51 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -229.72 Mn
10 Intensity Therapeutics 12.99 Mn 12.99 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2024 3.10 Mn
Sep 30, 2024 3.10 Mn
Jun 30, 2024 -6,000.00
Jun 30, 2024 -6,000.00
Mar 31, 2024 3.26 Mn
Mar 31, 2024 3.26 Mn
Dec 31, 2023 2.82 Mn
Dec 31, 2023 2.82 Mn
Sep 30, 2023 -8.84 Mn
Sep 30, 2023 -8.84 Mn